bioRxivMicrobiology
Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018-Impact and Lessons Learned
Y. C. Zhu, B. O'Brien, L. Leach, A. Clark, M. Bates, E. Adams, B. Ostrowsky, M. Quinn, E. Dufort, K. Southwick, R. Erazo, V. B. Haley, C. Bucher, V. Chaturvedi, R. J. Limberger, D. Blog, E. Lutterloh, S. Chaturvedi
Abstract
Candida auris is a multidrug-resistant yeast which has emerged in healthcare facilities worldwide, however little is known about identification methods, patient colonization, spread, environmental survival, and drug resistance. Colonization on both biotic and abiotic surfaces, along with travel, appear to be the major factors for the spread of this pathogen across the globe. In this investigation, we present laboratory findings from an ongoing C. auris outbreak in NY from August 2016 through 2018. A total of 540 clinical isolates, 11,035 patient surveillance specimens, and 3,672 environmental surveillance samples were analyzed. Laboratory methods included matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for yeast isolate identification, real-time PCR for rapid surveillance sample screening, culture on selective/non-selective media for recovery of C. auris and other yeasts from surveillance samples, antifungal susceptibility testing to determine the C. auris resistance profile, and Sanger sequencing of ribosomal genes for C. auris genotyping. Results included: a) identification and confirmation of C. auris in 413 clinical isolates and 931 patient surveillance isolates, as well as identification of 277 clinical cases and 350 colonized cases from 151 healthcare facilities including 59 hospitals, 92 nursing homes, 1 long-term acute care hospital (LTACH), and 2 hospices, b) successful utilization of an in-house developed C. auris real-time PCR assay for the rapid screening of patient and environmental surveillance samples, c) demonstration of relatively heavier colonization of C. auris in nares compared to the axilla/groin, and d) predominance of the South Asia Clade I with intrinsic resistance to fluconazole and elevated minimum inhibitory concentration (MIC) to voriconazole (81%), amphotericin B (61%), 5-FC (3%) and echinocandins (1%). These findings reflect greater regional prevalence and incidence of C. auris and the deployment of better detection tools in an unprecedented outbreak.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A rapid and automated sample-to-result Candida auris real-time PCR assay for high throughput testing of surveillance samples with BD MAX™ open system
L. Leach, A. Russell, … V. Chaturvedi·bioRxiv·Aug 5, 2019
- Reverse Transcriptase Real-Time PCR Assay for the Rapid Enumeration of Live Candida auris from the Healthcare Environment
Bryanna Lexus Freitas, Lynn Leach, … Sudha Chaturvedi·Journal of Clinical MicrobiologyPeer-reviewed·Dec 8, 2021
- High-Throughput, automated assay for detection of colonization by Candida auris
Francesca Scala, Brandon Schumitsch-Jewell, … Alana Sterkel·bioRxiv·Sep 1, 2026
- Candida auris: multi-omics signature of an emerging and multidrug-resistant pathogen
D. Zamith-Miranda, H. M. Heyman, … J. D. Nosanchuk·bioRxiv·Jan 23, 2019
- Development of Candida auris microsatellite typing and its application on a global collection of isolates
T. de Groot, Y. Puts, … J. Meis·bioRxiv·Oct 4, 2019
- Emergence of Candida auris in Minas Gerais, Brazil: Genomic Surveillance to inform Rapid Public Health Responses
Luíz Marcelo Ribeiro Tomé, Dhian Renato Almeida Camargo, … Talita Adelino·bioRxiv·Dec 13, 2024